Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus
NCT02194400
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL:
RSLV-132
Sponsor
Resolve Therapeutics